The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has recommended marketing approval for ocriplasmin (Jetrea, Thrombogenics, NV) for the treatment of adults with ...
ThromboGenics NV (Euronext Brussels: THR), an integrated biopharmaceutical company focused on developing and commercializing innovative ophthalmic medicines, today announces that its partner Alcon has ...
BRUSSELS (Reuters) – Belgian biotechnology company ThromboGenics said late on Monday that sales in the United States of its only drug, eye disease treatment Jetrea, had slowed in the second half of ...
JETREA is the first pharmacological treatment indicated for use in patients diagnosed with VMT, also when associated with macular hole of diameter less than or equal to 400 microns. It was approved ...
ThromboGenics NV, a biopharmaceutical company focused on developing and commercializing innovative ophthalmic medicines, announced that the UK’s National Institute for Health and Care Excellence (NICE ...
Leuven, March 16, 2015 - ThromboGenics NV (Euronext Brussels:THR), an integrated biopharmaceutical company focused on developing and commercializing innovative ophthalmic medicines, today announces ...
Patients in England and Wales with the serious eye condition vitreomacular traction will from this week have routine access to the first and only approved medicine for the condition, following the all ...
ThromboGenics NV has announced that the European Commission has approved JETREA® (ocriplasmin) in the European Union. JETREA® is approved for the treatment of vitreomacular traction (VMT), including ...
ThromboGenics NV has announced that its partner Alcon has launched JETREA® in Germany, the second European market where the product is now available. Since May 1st, 2013, JETREA® is listed in the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results